Assenagon Asset Management S.A. Has $2 Million Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)

Assenagon Asset Management S.A. raised its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 356.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 834,372 shares of the biopharmaceutical company's stock after purchasing an additional 651,480 shares during the period. Assenagon Asset Management S.A. owned 1.61% of Emergent BioSolutions worth $2,002,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of EBS. State Street Corp increased its position in Emergent BioSolutions by 25.7% during the second quarter. State Street Corp now owns 6,794,144 shares of the biopharmaceutical company's stock worth $49,937,000 after purchasing an additional 1,388,594 shares during the last quarter. BlackRock Inc. increased its position in shares of Emergent BioSolutions by 8.1% in the first quarter. BlackRock Inc. now owns 8,731,904 shares of the biopharmaceutical company's stock worth $358,533,000 after acquiring an additional 655,003 shares in the last quarter. Balyasny Asset Management LLC acquired a new stake in shares of Emergent BioSolutions in the third quarter worth $11,478,000. Charles Schwab Investment Management Inc. increased its position in shares of Emergent BioSolutions by 44.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,561,050 shares of the biopharmaceutical company's stock worth $5,308,000 after acquiring an additional 482,632 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth $5,016,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Emergent BioSolutions from a "sell" rating to a "hold" rating in a research report on Tuesday, December 12th. Benchmark raised shares of Emergent BioSolutions from a "hold" rating to a "buy" rating and set a $5.00 price objective for the company in a research report on Thursday, March 7th.

Emergent BioSolutions Stock Up 0.7 %

EBS traded up $0.02 during trading hours on Friday, reaching $2.29. 1,117,537 shares of the stock traded hands, compared to its average volume of 2,983,510. The firm's fifty day simple moving average is $2.31 and its two-hundred day simple moving average is $2.36. The company has a market cap of $119.28 million, a price-to-earnings ratio of -0.15 and a beta of 1.20. Emergent BioSolutions Inc. has a fifty-two week low of $1.42 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.04 and a quick ratio of 0.54.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.44). The firm had revenue of $276.60 million for the quarter, compared to analyst estimates of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same period in the previous year, the business posted ($0.31) earnings per share. As a group, analysts forecast that Emergent BioSolutions Inc. will post -13.98 earnings per share for the current fiscal year.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.